The FDA has said it has agreed to reconsider its decision to prevent compounding pharmacies from producing and selling versions of Eli Lilly's diabetes and obesity drug tirzepatide.
Eli Lilly's latest clinical readout for dual GIP/GLP-1 agonist tirzepatide is a big one, with data suggesting the drug can reduce the risk of developing type 2 diabetes in overweight and ob
Eli Lilly has raised its revenue guidance for 2024 by $3 billion, after reporting strong growth for tirzepatide in diabetes and obesity, fuelled by the end of supply constraints for startin
